DiaMedica Therapeutics 3/20/2024 Earnings Report $6.51 -0.10 (-1.51%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast DiaMedica Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.14Beat/MissMet ExpectationsOne Year Ago EPSN/ADiaMedica Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADiaMedica Therapeutics Announcement DetailsQuarterDate3/20/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseDMAC Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by DiaMedica Therapeutics Earnings HeadlinesDiaMedica Therapeutics publishes DM199 data in StrokeFebruary 21 at 7:53 PM | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)February 21 at 7:53 PM | markets.businessinsider.comNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long run … that's a good thing.February 23, 2025 | Weiss Ratings (Ad)DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal StrokeFebruary 20 at 8:34 AM | finance.yahoo.comDiaMedica Therapeutics (NASDAQ:DMAC) vs. Conduit Pharmaceuticals (NASDAQ:CDT) Head to Head SurveyFebruary 19, 2025 | americanbankingnews.comDiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 11, 2025 | finance.yahoo.comSee More DiaMedica Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DiaMedica Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your email. Email Address About DiaMedica TherapeuticsDiaMedica Therapeutics (NASDAQ:DMAC), a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.View DiaMedica Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
